Keeping Complex Chronic Pain Patients Alive During and After the COVID-19 Pandemic

  • Funded by Canadian Institutes of Health Research (CIHR)
  • Total publications:11 publications

Grant number: 173097

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2020
    2020
  • Known Financial Commitments (USD)

    $152,195.99
  • Funder

    Canadian Institutes of Health Research (CIHR)
  • Principal Investigator

    Hance A Clarke
  • Research Location

    Canada
  • Lead Research Institution

    University Health Network
  • Research Priority Alignment

    N/A
  • Research Category

    Secondary impacts of disease, response & control measures

  • Research Subcategory

    Indirect health impacts

  • Special Interest Tags

    Digital Health

  • Study Type

    Clinical

  • Clinical Trial Details

    Not applicable

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    OtherUnspecified

  • Occupations of Interest

    Unspecified

Abstract

Chronic pain affects nearly 20% of Canadians, and sixty percent or more of individuals with chronic pain are also struggling with mental health or substance use disorders (referred to as complex chronic pain, or CCP, patients). This is a major concern in the best of times and has become an emergency during the COVID-19 pandemic. Now individuals suffering from chronic pain are faced with the additional challenges of quarantine, including the stress of isolation, delays in much needed medical care, and anxiety of possible infection to self or loved ones. Prior to COVID-19, psychologists at The Transitional Pain Service and the GoodHope Ehlers-Danlos Syndrome Clinic at Toronto General Hospital have adapted gold standard treatments for mental health and substance use for the unique needs of individuals with CCP. We propose to develop these treatments into a virtual intervention that will meet the needs of patients during and after the COVID-19 pandemic. We will use a mobile health application (called Manage My Pain or MMP) already in use by our patients to identify patients with CCP currently struggling with mental health issues or at risk of opioid misuse. With CIHR support, we will be able to offer treatment to these vulnerable patients throughout Ontario and Alberta from Toronto General Hospital and our partner sites at the Opioid Deprescribing Program in Calgary and the Centenary Pain Clinic in Toronto. We will also help patients with chronic pain across the country access these treatments by creating an educational website with self-help materials and information for providers. This project will provide much needed mental health care to thousands of Canadians during this crisis and will develop the infrastructure to ensure greater availability of high quality psychological care for patients with chronic pain once the crisis has passed.

Publicationslinked via Europe PMC

Last Updated:an hour ago

View all publications at Europe PMC

Macrocyclization of backbone <i>N</i>-methylated peptides by a prolyl oligopeptidase with a distinctive substrate recognition mechanism.

Structural and Functional Analysis of Peptides Derived from KEX2-Processed Repeat Proteins in Agaricomycetes Using Reverse Genetics and Peptidomics.

Injection into and extraction from single fungal cells.

Cytoplasmic Lipases-A Novel Class of Fungal Defense Proteins Against Nematodes.

Marasmius oreades agglutinin enhances resistance of Arabidopsis against plant-parasitic nematodes and a herbivorous insect.

Identification, heterologous production and bioactivity of lentinulin A and dendrothelin A, two natural variants of backbone N-methylated peptide macrocycle omphalotin A.

Heterologous Production and Functional Characterization of Ageritin, a Novel Type of Ribotoxin Highly Expressed during Fruiting of the Edible Mushroom Agrocybe aegerita.

Combining microfluidics and RNA-sequencing to assess the inducible defensome of a mushroom against nematodes.